NCT06589518View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions

Hepatitis B VirusLiver TransplantRenal Insufficiency

Interventions

DRUG

Tenofovir Alafenamide Citrate

Tenofovir alafenamide is administered once every day with 25mg PO for 48 weeks.

All Listed Sponsors

lead

Jongman Kim

OTHER